Abstract | AIMS: METHODS:
Levosimendan was administered as a continuous intravenous infusion for 7 days. Twelve subjects received the drug at an infusion rate of 0.05 micro g kg(-1) min(-1) and 12 at a rate 0.1 micro g kg(-1) min(-1). RESULTS: Steady state concentrations of levosimendan were achieved within 4 h. Peak concentrations of the metabolites occurred after termination of the infusion. The mean (+/- SD) half-life of the active metabolite OR-1896 was 81 +/- 37 h after the lower dose and 81 +/- 28 h after the higher dose (P = 0.992, 95% confidence interval on the difference -27.5, 27.7). CONCLUSIONS: The metabolites of levosimendan, OR-1855 and OR-1896, were formed and eliminated slowly, their peak concentrations occurring after termination of the 7-day infusion of the drug.
|
Authors | Saila Antila, Matti Kivikko, Lasse Lehtonen, Jaan Eha, Aira Heikkilä, Pasi Pohjanjousi, Pertti J Pentikäinen |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 57
Issue 4
Pg. 412-5
(Apr 2004)
ISSN: 0306-5251 [Print] England |
PMID | 15025738
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Acetamides
- Cardiotonic Agents
- Hydrazones
- N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide
- Pyridazines
- Simendan
|
Topics |
- Acetamides
(metabolism)
- Cardiotonic Agents
(administration & dosage, pharmacokinetics)
- Female
- Heart Failure
(drug therapy, metabolism)
- Humans
- Hydrazones
(administration & dosage, metabolism, pharmacokinetics)
- Infusions, Intravenous
- Male
- Protein Binding
- Pyridazines
(administration & dosage, metabolism, pharmacokinetics)
- Simendan
|